Contrave Now Available for Chronic Weight Management

Takeda and Orexigen announced that Contrave (naltrexone HCl and bupropion HCl) extended-release tablets are now available by prescription. Contrave was approved in September 2014 as adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of  ≥30kg/m2 (obese) or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition. 

RELATED: New Combo Tablet for Weight Management Approved

Contrave combines naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Some studies suggest naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system). However, the exact neurochemical effects of Contrave resulting in weight loss are not fully understood. 

Contrave is available in 8mg/90mg extended-release tablets in 120-count bottles. 

For more information call (877) 825-3327 or visit